have evolved
Harnessing more of the immune system for better cancer outcomes
Latest News

Well deserved recognition for @ProfSharonLewin picking up the top gong from @Committee4Melb A virologist and director, we collectively looked to Sharon for advice on Melbourne's response to the pandemic. An incredible response from a remarkable leader


Congratulations ⁦@ProfSharonLewin⁩ !

New low budget PR video from the power saddle @MonashBDI Recent @jlb_journal article from now @oNKo_innate crew on primary human NK cell editing with #CRISPR RNP. No @OceanSprayInc cranberry but the fine folk @iamspecialized have provided the S-Works SL7 ride #innovation #nkcell

Journal of Leukocyte Biology@jlb_journal

Another great #NK paper this month in #JLB! In this issue, @Dr_Nick_Bikes discusses the use of CRISPR RNP for drug target validation in primary human NK cells in #Cancer #Immunotherapy. Check it out -

Load More...
Discover oNKo-innate
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
Learn more
Using powerful genomic approaches, we screen primary immune cells and cancer cells to understand their interaction within a tumor.
Learn more
o o
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
Find out who we are